Wells Fargo Raises Bio-Rad Laboratories (NYSE: BIO) Price Target Amid Elliott Investment Management's Stake and Sartorius Holdings

  • Wells Fargo increased its price target for Bio-Rad Laboratories (NYSE: BIO) to $310, signaling a positive outlook for the global supplier of life science research and clinical diagnostics tools.
  • Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories, aiming to influence strategy and unlock value, especially after a 70% stock decline from its peak.
  • Bio-Rad Laboratories' substantial $5 billion investment in Sartorius, coupled with Elliott Investment Management's dual investment in both companies, presents a unique opportunity for strategic changes to improve financial performance and shareholder returns.

On May 25, 2026, Wells Fargo raises its price target for Bio-Rad Laboratories (NYSE: BIO) to $310 from a previous target of $290. Bio-Rad Laboratories is a global supplier of tools and services for the life science research and clinical diagnostics markets. The analyst update occurs while BIO's stock price is $287.74.

This positive outlook comes as activist investor Elliott Investment Management builds a large stake in Bio-Rad Laboratories. An activist investor is a person or group that buys a significant amount of a company's stock. They use this ownership to influence the company's management and strategy, often to increase the stock's value.

The interest from Elliott Investment Management follows a period of significant strain for the company. As highlighted by The Wall Street Journal, BIO's shares have collapsed by more than 70% from their peak in late 2021. Such a large drop in price can attract investors who see an opportunity to push for changes and unlock value.

A key point of focus is Bio-Rad Laboratories' large investment in the German company Sartorius. BIO's stake in Sartorius is valued at about $5 billion. This is a substantial part of BIO's own market capitalization, which is approximately $7.78 billion. This large holding could be central to an activist's strategy.

Elliott Investment Management is also a large investor in Sartorius, creating a unique situation. This dual investment may allow Elliott Investment Management to push for changes regarding Bio-Rad Laboratories' structure or its relationship with Sartorius. Such actions could be aimed at improving Bio-Rad Laboratories' financial performance and shareholder returns, supporting the higher price target from Wells Fargo.

About the Author
Danny Green

Market news and analyst rating coverage

Danny Green writes market news and analyst-rating coverage for the FMP blog, tracking broker upgrades and downgrades, price-target changes, and earnings developments. His posts distill the latest market events into concise, data-driven updates for investors.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account